{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:59:30Z","timestamp":1786996770877,"version":"build-2736575974"},"reference-count":128,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T00:00:00Z","timestamp":1770854400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009093","name":"Fundaci\u00f3n Espa\u00f1ola de Hematolog\u00eda y Hemoterapia","doi-asserted-by":"publisher","award":["FEHH_BECAS24_01"],"award-info":[{"award-number":["FEHH_BECAS24_01"]}],"id":[{"id":"10.13039\/501100009093","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018693","name":"HORIZON EUROPE Framework Programme","doi-asserted-by":"publisher","award":["101222226"],"award-info":[{"award-number":["101222226"]}],"id":[{"id":"10.13039\/100018693","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["24566"],"award-info":[{"award-number":["24566"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["CP25\/00084"],"award-info":[{"award-number":["CP25\/00084"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020581","name":"Fondazione AIRC per la ricerca sul cancro ETS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020581","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Cancer Biology"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.semcancer.2026.02.002","type":"journal-article","created":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T00:21:23Z","timestamp":1771028483000},"page":"48-60","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["The biology and evolution of Richter transformation in chronic lymphocytic leukemia"],"prefix":"10.1016","volume":"120","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2910-9440","authenticated-orcid":false,"given":"Ferran","family":"Nadeu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitar G.","family":"Efremov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semcancer.2026.02.002_bib1","first-page":"285","article-title":"Generalized reticular cell sarcoma of lymph nodes associated with lymphatic leukemia","volume":"4","author":"Richter","year":"1928","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.semcancer.2026.02.002_bib2","series-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (Revised 4t edition)","author":"Swerdlow","year":"2017"},{"key":"10.1016\/j.semcancer.2026.02.002_bib3","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.semcancer.2026.02.002_bib4","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1182\/blood.2022015851","article-title":"The international consensus classification of mature lymphoid neoplasms: a report from the clinical advisory committee","volume":"140","author":"Campo","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2026.02.002_bib5","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1200\/JCO.2005.05.0187","article-title":"Clinical outcomes and prognostic factors in patients with Richter\u2019s syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation","volume":"24","author":"Tsimberidou","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2026.02.002_bib6","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1111\/bjh.12458","article-title":"Diffuse large B-cell lymphoma (Richter syndrome) in patients with chronic lymphocytic leukaemia (CLL): a cohort study of newly diagnosed patients","volume":"162","author":"Parikh","year":"2013","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.semcancer.2026.02.002_bib7","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.canep.2019.04.002","article-title":"Richter syndrome epidemiology in a large population based chronic lymphocytic leukemia cohort from Norway","volume":"60","author":"Lenartova","year":"2019","journal-title":"Cancer Epidemiol."},{"key":"10.1016\/j.semcancer.2026.02.002_bib8","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1080\/10428194.2020.1719092","article-title":"Richter\u2019s transformation in patients with chronic lymphocytic leukaemia: a nationwide epidemiological study","volume":"61","author":"Ben-Dali","year":"2020","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.semcancer.2026.02.002_bib9","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1007\/s00277-021-04603-y","article-title":"Outcomes of Richter\u2019s transformation of chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL): an analysis of the SEER database","volume":"100","author":"Elnair","year":"2021","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.semcancer.2026.02.002_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2023.102619","article-title":"From genetics to therapy: unraveling the complexities of Richter transformation in chronic lymphocytic leukemia","volume":"120","author":"Abrisqueta","year":"2023","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.semcancer.2026.02.002_bib11","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.3324\/haematol.2019.240564","article-title":"The role of 18F-FDG-PET in detecting Richter\u2019s transformation of chronic lymphocytic leukemia in patients receiving therapy with a B-cell receptor inhibitor","volume":"105","author":"Wang","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.semcancer.2026.02.002_bib12","first-page":"1267","article-title":"Detection of Richter\u2019s transformation of chronic lymphocytic leukemia by PET\/CT","volume":"47","author":"Bruzzi","year":"2006","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.semcancer.2026.02.002_bib13","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.3324\/haematol.2010.022277","article-title":"Expanded and highly active proliferation centers identify a histological subtype of chronic lymphocytic leukemia (\u201caccelerated\u201d chronic lymphocytic leukemia) with aggressive clinical behavior","volume":"95","author":"Gine","year":"2010","journal-title":"Haematologica"},{"issue":"43","key":"10.1016\/j.semcancer.2026.02.002_bib14","doi-asserted-by":"crossref","DOI":"10.1200\/EDBK_390804","article-title":"Practical management of Richter transformation in 2023 and beyond","author":"Ryan","year":"2023","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"10.1016\/j.semcancer.2026.02.002_bib15","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1182\/blood.2024028064","article-title":"International consensus statement on diagnosis, evaluation, and research of Richter transformation: the ERIC recommendations","volume":"146","author":"Kittai","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2026.02.002_bib16","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/j.1365-2141.2008.07166.x","article-title":"Biological and clinical risk factors of chronic lymphocytic leukaemia transformation to Richter syndrome","volume":"142","author":"Rossi","year":"2008","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.semcancer.2026.02.002_bib17","doi-asserted-by":"crossref","first-page":"868","DOI":"10.3324\/haematol.2021.278304","article-title":"The complex karyotype landscape in chronic lymphocytic leukemia allows the refinement of the risk of Richter syndrome transformation","volume":"107","author":"Visentin","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.semcancer.2026.02.002_bib18","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1182\/bloodadvances.2017007302","article-title":"Near-tetraploidy is associated with Richter transformation in chronic lymphocytic leukemia patients receiving ibrutinib","volume":"1","author":"Miller","year":"2017","journal-title":"Blood Adv."},{"key":"10.1016\/j.semcancer.2026.02.002_bib19","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1038\/leu.2012.357","article-title":"NOTCH1 mutations identify a genetic subgroup of chronic lymphocytic leukemia patients with high risk of transformation and poor outcome","volume":"27","author":"Villamor","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.semcancer.2026.02.002_bib20","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1111\/j.1365-2141.2012.09155.x","article-title":"Different impact of NOTCH1 and SF3B1 mutations on the risk of chronic lymphocytic leukemia transformation to Richter syndrome","volume":"158","author":"Rossi","year":"2012","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.semcancer.2026.02.002_bib21","doi-asserted-by":"crossref","first-page":"4415","DOI":"10.1158\/1078-0432.CCR-08-3266","article-title":"Stereotyped B-cell receptor is an independent risk factor of chronic lymphocytic leukemia transformation to Richter syndrome","volume":"15","author":"Rossi","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.semcancer.2026.02.002_bib22","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.1182\/blood-2010-09-302174","article-title":"The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation","volume":"117","author":"Rossi","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2026.02.002_bib23","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1084\/jem.20131448","article-title":"Genetic lesions associated with chronic lymphocytic leukemia transformation to Richter syndrome","volume":"210","author":"Fabbri","year":"2013","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.semcancer.2026.02.002_bib24","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1182\/blood-2013-03-489518","article-title":"Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndrome","volume":"122","author":"Chigrinova","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2026.02.002_bib25","doi-asserted-by":"crossref","first-page":"2800","DOI":"10.1182\/blood.2020005650","article-title":"Genomic and transcriptomic correlates of Richter transformation in chronic lymphocytic leukemia","volume":"137","author":"Klintman","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2026.02.002_bib26","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1038\/s41591-022-01927-8","article-title":"Detection of early seeding of Richter transformation in chronic lymphocytic leukemia","volume":"28","author":"Nadeu","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.semcancer.2026.02.002_bib27","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/s41591-022-02113-6","article-title":"Evolutionary history of transformation from chronic lymphocytic leukemia to Richter syndrome","volume":"29","author":"Parry","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.semcancer.2026.02.002_bib28","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-017-00210-6","article-title":"Two mouse models reveal an actionable PARP1 dependence in aggressive chronic lymphocytic leukemia","volume":"8","author":"Knittel","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.semcancer.2026.02.002_bib29","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1182\/blood.2020005734","article-title":"Active Akt signaling triggers CLL toward Richter transformation via overactivation of Notch1","volume":"137","author":"Kohlhaas","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2026.02.002_bib30","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1182\/blood.2020008276","article-title":"B-cell receptor signaling and genetic lesions in TP53 and CDKN2A\/CDKN2B cooperate in Richter transformation","volume":"138","author":"Chakraborty","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2026.02.002_bib31","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1182\/blood.2022016272","article-title":"Macrophage- and BCR-derived but not TLR-derived signals support the growth of CLL and Richter syndrome murine models in vivo","volume":"140","author":"Martines","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2026.02.002_bib32","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1158\/2643-3230.BCD-22-0082","article-title":"In vivo modeling of CLL transformation to Richter syndrome reveals convergent evolutionary paths and therapeutic vulnerabilities","volume":"4","author":"Ten Hacken","year":"2023","journal-title":"Blood Cancer Discov."},{"key":"10.1016\/j.semcancer.2026.02.002_bib33","doi-asserted-by":"crossref","first-page":"3413","DOI":"10.1158\/0008-5472.CAN-17-4004","article-title":"Novel Richter syndrome xenograft models to study genetic architecture, biology, and therapy responses","volume":"78","author":"Vaisitti","year":"2018","journal-title":"Cancer Res"},{"key":"10.1016\/j.semcancer.2026.02.002_bib34","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1038\/s41375-022-01604-2","article-title":"Immunoglobulin gene sequence analysis in chronic lymphocytic leukemia: the 2022 update of the recommendations by ERIC, the European Research Initiative on CLL","volume":"36","author":"Agathangelidis","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.semcancer.2026.02.002_bib35","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41375-024-02163-4","article-title":"Updates of the ERIC recommendations on how to report the results from immunoglobulin heavy variable gene analysis in chronic lymphocytic leukemia","volume":"38","author":"Chatzikonstantinou","year":"2024","journal-title":"Leukemia"},{"key":"10.1016\/j.semcancer.2026.02.002_bib36","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1038\/s41375-019-0496-7","article-title":"Standardized next-generation sequencing of immunoglobulin and T-cell receptor gene recombinations for MRD marker identification in acute lymphoblastic leukaemia; a EuroClonality-NGS validation study","volume":"33","author":"Br\u00fcggemann","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.semcancer.2026.02.002_bib37","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000962","article-title":"All-CLL: A capture-based next-generation sequencing panel for the molecular characterization of chronic lymphocytic leukemia","volume":"7","author":"L\u00f3pez-Oreja","year":"2023","journal-title":"Hemasphere"},{"key":"10.1016\/j.semcancer.2026.02.002_bib38","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1182\/bloodadvances.2024015594","article-title":"Clonal relatedness as a prognostic marker in Richter transformation of chronic lymphocytic leukemia: a systematic review","volume":"9","author":"Barrett","year":"2025","journal-title":"Blood Adv."},{"key":"10.1016\/j.semcancer.2026.02.002_bib39","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1111\/bjh.16748","article-title":"Clinical outcome and prognostic factors of patients with Richter syndrome: real-world study of the Spanish Chronic Lymphocytic Leukemia Study Group (GELLC)","volume":"190","author":"Abrisqueta","year":"2020","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.semcancer.2026.02.002_bib40","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/s41467-022-34642-6","article-title":"Molecular characterization of Richter syndrome identifies de novo diffuse large B-cell lymphomas with poor prognosis","volume":"14","author":"Bros\u00e9us","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.semcancer.2026.02.002_bib41","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1097\/PAS.0b013e31804bdaf8","article-title":"IgVH mutational status and clonality analysis of Richter\u2019s transformation: diffuse large B-cell lymphoma and Hodgkin lymphoma in association with B-cell chronic lymphocytic leukemia (B-CLL) represent 2 different pathways of disease evolution","volume":"31","author":"Mao","year":"2007","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.semcancer.2026.02.002_bib42","doi-asserted-by":"crossref","first-page":"765","DOI":"10.3324\/haematol.2019.224121","article-title":"Clinical characteristics and outcomes of Richter transformation: experience of 204 patients from a single center","volume":"105","author":"Wang","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.semcancer.2026.02.002_bib43","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1016\/S1470-2045(24)00396-6","article-title":"Atezolizumab, venetoclax, and obinutuzumab combination in Richter transformation diffuse large B-cell lymphoma (MOLTO): a multicentre, single-arm, phase 2 trial","volume":"25","author":"Tedeschi","year":"2024","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.semcancer.2026.02.002_bib44","doi-asserted-by":"crossref","first-page":"e682","DOI":"10.1016\/S2352-3026(24)00172-8","article-title":"Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in patients with B-cell malignancies: analysis of the Richter transformation subgroup from the multicentre, open-label, phase 1\/2 BRUIN study","volume":"11","author":"Wierda","year":"2024","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.semcancer.2026.02.002_bib45","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.pathol.2022.12.354","article-title":"Immunophenotypic and genomic landscape of Richter transformation diffuse large B-cell lymphoma","volume":"55","author":"El Hussein","year":"2023","journal-title":"Pathology"},{"key":"10.1016\/j.semcancer.2026.02.002_bib46","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41591-018-0016-8","article-title":"Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes","volume":"24","author":"Chapuy","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.semcancer.2026.02.002_bib47","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa1801445","article-title":"Genetics and pathogenesis of diffuse large B-cell lymphoma","volume":"378","author":"Schmitz","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.semcancer.2026.02.002_bib48","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.ccell.2020.03.015","article-title":"A probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications","volume":"37","author":"Wright","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.semcancer.2026.02.002_bib49","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/35000501","article-title":"Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling","volume":"403","author":"Alizadeh","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.semcancer.2026.02.002_bib50","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2024.286380","article-title":"Chronic lymphocytic leukemia often arises by a multiclonal selection process","author":"Bagnara","year":"2025","journal-title":"Haematologica"},{"key":"10.1016\/j.semcancer.2026.02.002_bib51","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1111\/bjh.18352","article-title":"Clonally unrelated Richter syndrome are truly de novo diffuse large B-cell lymphomas with a mutational profile reminiscent of clonally related Richter syndrome","volume":"198","author":"Favini","year":"2022","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.semcancer.2026.02.002_bib52","doi-asserted-by":"crossref","first-page":"868","DOI":"10.3324\/haematol.2021.278304","article-title":"The complex karyotype landscape in chronic lymphocytic leukemia allows the refinement of the risk of Richter syndrome transformation","volume":"107","author":"Visentin","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.semcancer.2026.02.002_bib53","doi-asserted-by":"crossref","first-page":"4783","DOI":"10.1182\/blood-2012-04-423517","article-title":"High-resolution genomic profiling of chronic lymphocytic leukemia reveals new recurrent genomic alterations","volume":"120","author":"Edelmann","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2026.02.002_bib54","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/nature14666","article-title":"Non-coding recurrent mutations in chronic lymphocytic leukaemia","volume":"526","author":"Puente","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.semcancer.2026.02.002_bib55","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3324\/haematol.2019.239947","article-title":"Genomic arrays identify high-risk chronic lymphocytic leukemia with genomic complexity: a multi-center study","volume":"106","author":"Leeksma","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.semcancer.2026.02.002_bib56","doi-asserted-by":"crossref","first-page":"E159","DOI":"10.1002\/ajh.26479","article-title":"TP53 mutations at codon 234 are associated with chlorambucil treatment in chronic lymphocytic leukemia","volume":"97","author":"Lazarian","year":"2022","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.semcancer.2026.02.002_bib57","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/s41375-020-0797-x","article-title":"Richter transformation in chronic lymphocytic leukemia (CLL)-a pooled analysis of German CLL Study Group (GCLLSG) front line treatment trials","volume":"35","author":"Al-Sawaf","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.semcancer.2026.02.002_bib58","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1038\/leu.2016.113","article-title":"Effect of first-line treatment on second primary malignancies and Richter\u2019s transformation in patients with CLL","volume":"30","author":"Maurer","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.semcancer.2026.02.002_bib59","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/s41375-024-02492-4","article-title":"Incidence of Richter transformation of chronic lymphocytic leukemia\/small lymphocytic lymphoma in the targeted therapy era","volume":"39","author":"Hampel","year":"2025","journal-title":"Leukemia"},{"key":"10.1016\/j.semcancer.2026.02.002_bib60","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.3109\/10428194.2012.723706","article-title":"MGA, a suppressor of MYC, is recurrently inactivated in high risk chronic lymphocytic leukemia","volume":"54","author":"De Paoli","year":"2013","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.semcancer.2026.02.002_bib61","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1002\/hon.932","article-title":"Genomic profiling of Richter\u2019s syndrome: recurrent lesions and differences with de novo diffuse large B-cell lymphomas","volume":"28","author":"Scandurra","year":"2010","journal-title":"Hematol. Oncol."},{"key":"10.1016\/j.semcancer.2026.02.002_bib62","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1182\/blood-2004-07-2947","article-title":"Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response","volume":"105","author":"Monti","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2026.02.002_bib63","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.ccr.2012.08.014","article-title":"Metabolic signatures uncover distinct targets in molecular subsets of diffuse large B cell lymphoma","volume":"22","author":"Caro","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1016\/j.semcancer.2026.02.002_bib64","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/cdd.2016.116","article-title":"Differential contribution of the mitochondrial translation pathway to the survival of diffuse large B-cell lymphoma subsets","volume":"24","author":"Norberg","year":"2017","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.semcancer.2026.02.002_bib65","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms15746","article-title":"Distinct homotypic B-cell receptor interactions shape the outcome of chronic lymphocytic leukaemia","volume":"8","author":"Minici","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.semcancer.2026.02.002_bib66","article-title":"Co-mapping clonal and transcriptional heterogeneity in somatic evolution via GoT-Multi","author":"Pak","year":"2025","journal-title":"Cell Genom."},{"key":"10.1016\/j.semcancer.2026.02.002_bib67","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1111\/bjh.18952","article-title":"Clonal architecture and single-cell transcriptome landscape in Richter\u2019s syndrome","volume":"202","author":"Li","year":"2023","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.semcancer.2026.02.002_bib68","doi-asserted-by":"crossref","DOI":"10.1093\/bib\/bbaf516","article-title":"Numbat-multiome: inferring copy number variations by combining RNA and chromatin accessibility information from single-cell data","volume":"26","author":"Li","year":"2025","journal-title":"Brief. Bioinform"},{"key":"10.1016\/j.semcancer.2026.02.002_bib69","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1038\/s41586-025-09374-4","article-title":"Fluctuating DNA methylation tracks cancer evolution at clinical scale","volume":"645","author":"Gabbutt","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.semcancer.2026.02.002_bib70","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1200\/JCO.2016.70.2282","article-title":"BTKC481S-mediated resistance to ibrutinib in chronic lymphocytic leukemia","volume":"35","author":"Woyach","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2026.02.002_bib71","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1200\/JCO.21.01210","article-title":"Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: Results of the first randomized phase III trial","volume":"39","author":"Byrd","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2026.02.002_bib72","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1038\/s41379-019-0356-z","article-title":"Chronic lymphocytic leukemia with TP53 gene alterations: a detailed clinicopathologic analysis","volume":"33","author":"Liu","year":"2020","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.semcancer.2026.02.002_bib73","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1007\/s00428-024-03920-7","article-title":"Accelerated\u201d chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL): unraveling the biological gray zone of CLL\/SLL in the era of novel therapies","volume":"486","author":"Vadasz","year":"2025","journal-title":"Virchows Arch."},{"key":"10.1016\/j.semcancer.2026.02.002_bib74","doi-asserted-by":"crossref","first-page":"28","DOI":"10.5114\/wo.2025.149235","article-title":"Accelerated chronic lymphocytic leukemia \u2013 characteristics and retrospective analysis of the Polish Adult Leukemia Study Group","volume":"29","author":"So\u015bnia","year":"2025","journal-title":"Wsp\u00f3\u0142czesna Onkol."},{"key":"10.1016\/j.semcancer.2026.02.002_bib75","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/s41408-021-00477-5","article-title":"Distinct immune signatures in chronic lymphocytic leukemia and Richter syndrome","volume":"11","author":"Wang","year":"2021","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.semcancer.2026.02.002_bib76","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1016\/j.ccell.2023.08.013","article-title":"ZNF683 marks a CD8+ T cell population associated with anti-tumor immunity following anti-PD-1 therapy for Richter syndrome","volume":"41","author":"Parry","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.semcancer.2026.02.002_bib77","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/bjh.17789","article-title":"Characterisation of immune checkpoints in Richter syndrome identifies LAG3 as a potential therapeutic target","volume":"195","author":"Gould","year":"2021","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.semcancer.2026.02.002_bib78","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.ccell.2021.01.003","article-title":"Mutant p53 suppresses innate immune signaling to promote tumorigenesis","volume":"39","author":"Ghosh","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.semcancer.2026.02.002_bib79","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-25894-9","article-title":"9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapy","volume":"12","author":"Han","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.semcancer.2026.02.002_bib80","doi-asserted-by":"crossref","first-page":"6220","DOI":"10.1038\/s41467-022-33739-2","article-title":"Viral transduction of primary human lymphoma B cells reveals mechanisms of NOTCH-mediated immune escape","volume":"13","author":"Mangolini","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.semcancer.2026.02.002_bib81","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1038\/s41375-024-02224-8","article-title":"NFKBIE mutations are selected by the tumor microenvironment and contribute to immune escape in chronic lymphocytic leukemia","volume":"38","author":"Bonato","year":"2024","journal-title":"Leukemia"},{"key":"10.1016\/j.semcancer.2026.02.002_bib82","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1097\/PAS.0000000000001077","article-title":"PD-1 expression in chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL) and large B-cell Richter transformation (DLBCL-RT): a characteristic feature of DLBCL-RT and potential surrogate marker for clonal relatedness","volume":"42","author":"He","year":"2018","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.semcancer.2026.02.002_bib83","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1111\/bjh.15514","article-title":"PD-1 is highly expressed by neoplastic B-cells in Richter transformation","volume":"185","author":"Behdad","year":"2019","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.semcancer.2026.02.002_bib84","doi-asserted-by":"crossref","first-page":"953","DOI":"10.3324\/haematol.2012.077537","article-title":"The PD-1\/PD-L1 axis contributes to T-cell dysfunction in chronic lymphocytic leukemia","volume":"98","author":"Brusa","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.semcancer.2026.02.002_bib85","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0035178","article-title":"Programmed death-1 and its ligand are novel immunotolerant molecules expressed on leukemic B cells in chronic lymphocytic leukemia","volume":"7","author":"Grzywnowicz","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.semcancer.2026.02.002_bib86","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2426935122","article-title":"PD-1 expression identifies proliferating malignant CLL B cells and is a potential biomarker of response to BTK inhibitor therapy","volume":"122","author":"Chang","year":"2025","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.semcancer.2026.02.002_bib87","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1016\/j.cell.2015.08.052","article-title":"Melanoma cell-intrinsic PD-1 receptor functions promote tumor growth","volume":"162","author":"Kleffel","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.semcancer.2026.02.002_bib88","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15041015","article-title":"Immunological aspects of Richter syndrome: from immune dysfunction to immunotherapy","volume":"15","author":"Mahmoud","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.semcancer.2026.02.002_bib89","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1158\/2159-8290.CD-15-1408","article-title":"PD-1hi identifies a novel regulatory B-cell population in human hepatoma that promotes disease progression","volume":"6","author":"Xiao","year":"2016","journal-title":"Cancer Discov."},{"key":"10.1016\/j.semcancer.2026.02.002_bib90","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.molimm.2019.02.009","article-title":"PD-1-expressing B cells suppress CD4+ and CD8+ T cells via PD-1\/PD-L1-dependent pathway","volume":"109","author":"Wang","year":"2019","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.semcancer.2026.02.002_bib91","doi-asserted-by":"crossref","first-page":"3419","DOI":"10.1182\/blood-2017-02-765685","article-title":"Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL","volume":"129","author":"Ding","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2026.02.002_bib92","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.1016\/S2352-3026(18)30217-5","article-title":"Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1\/2a study","volume":"6","author":"Younes","year":"2019","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.semcancer.2026.02.002_bib93","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1182\/bloodadvances.2022008790","article-title":"A phase 2 study of nivolumab combined with ibrutinib in patients with diffuse large B-cell Richter transformation of CLL","volume":"7","author":"Jain","year":"2023","journal-title":"Blood Adv."},{"key":"10.1016\/j.semcancer.2026.02.002_bib94","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1038\/s41591-023-02722-9","article-title":"Tislelizumab plus zanubrutinib for Richter transformation: the phase 2 RT1 trial","volume":"30","author":"Al-Sawaf","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.semcancer.2026.02.002_bib95","article-title":"Efficacy of pembrolizumab monotherapy and in combination with BCR inhibitors for Richter transformation of chronic lymphocytic leukemia (CLL)","volume":"42","author":"Wang","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2026.02.002_bib96","doi-asserted-by":"crossref","first-page":"6955","DOI":"10.1073\/pnas.102181599","article-title":"Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression","volume":"99","author":"Bichi","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.semcancer.2026.02.002_bib97","doi-asserted-by":"crossref","first-page":"11713","DOI":"10.1073\/pnas.0604564103","article-title":"B cell receptors in TCL1 transgenic mice resemble those of aggressive, treatment-resistant human chronic lymphocytic leukemia","volume":"103","author":"Yan","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.semcancer.2026.02.002_bib98","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1038\/s41375-018-0260-4","article-title":"Exome sequencing of the TCL1 mouse model for CLL reveals genetic heterogeneity and dynamics during disease development","volume":"33","author":"Zaborsky","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.semcancer.2026.02.002_bib99","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/s41375-021-01381-4","article-title":"Longitudinal analyses of CLL in mice identify leukemia-related clonal changes including a Myc gain predicting poor outcome in patients","volume":"36","author":"\u00d6zt\u00fcrk","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.semcancer.2026.02.002_bib100","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ccr.2009.11.019","article-title":"The DLEU2\/miR-15a\/16-1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia","volume":"17","author":"Klein","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1016\/j.semcancer.2026.02.002_bib101","doi-asserted-by":"crossref","first-page":"6260","DOI":"10.1158\/1078-0432.CCR-19-0273","article-title":"E\u03bc-TCL1xMyc: a novel mouse model for concurrent CLL and B-cell lymphoma","volume":"25","author":"Lucas","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.semcancer.2026.02.002_bib102","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1158\/2159-8290.CD-17-1409","article-title":"The BTK inhibitor ARQ 531 targets ibrutinib-resistant CLL and Richter transformation","volume":"8","author":"Reiff","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.semcancer.2026.02.002_bib103","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1038\/s41375-025-02557-y","article-title":"Bcor loss promotes Richter transformation of chronic lymphocytic leukemia associated with Notch1 activation in mice","volume":"39","author":"Rompietti","year":"2025","journal-title":"Leukemia"},{"key":"10.1016\/j.semcancer.2026.02.002_bib104","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1038\/s41588-022-01140-w","article-title":"Molecular map of chronic lymphocytic leukemia and its impact on outcome","volume":"54","author":"Knisbacher","year":"2022","journal-title":"Nat. Genet."},{"key":"10.1016\/j.semcancer.2026.02.002_bib105","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adg7915","article-title":"MGA deletion leads to Richter\u2019s transformation by modulating mitochondrial OXPHOS","volume":"16","author":"Iyer","year":"2024","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.semcancer.2026.02.002_bib106","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.184280","article-title":"SF3B1 mutation accelerates the development of CLL via activation of the mTOR pathway","volume":"10","author":"Zhang","year":"2025","journal-title":"JCI Insight"},{"key":"10.1016\/j.semcancer.2026.02.002_bib107","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-017-00830-y","article-title":"NFAT2 is a critical regulator of the anergic phenotype in chronic lymphocytic leukaemia","volume":"8","author":"M\u00e4rklin","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.semcancer.2026.02.002_bib108","doi-asserted-by":"crossref","first-page":"3879","DOI":"10.1182\/blood-2012-12-474718","article-title":"Targeting B-cell anergy in chronic lymphocytic leukemia","volume":"121","author":"Apollonio","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2026.02.002_bib109","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1182\/blood-2024-207095","article-title":"Richter syndrome-associated genetic lesions in TP53 and the cell cycle inhibitors CDKN2A and CDKN2B induce transformation of a CD5+ B cell subset characterized by a restricted IGHV repertoire, autoreactivity and BCR dependence","volume":"144","author":"Martines","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2026.02.002_bib110","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.592205","article-title":"Proliferative signals in chronic lymphocytic leukemia; what are we missing?","volume":"10","author":"Haselager","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.semcancer.2026.02.002_bib111","doi-asserted-by":"crossref","first-page":"3365","DOI":"10.1182\/blood.2020008404","article-title":"ROR1 targeting with the antibody-drug conjugate VLS-101 is effective in Richter syndrome patient-derived xenograft mouse models","volume":"137","author":"Vaisitti","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2026.02.002_bib112","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1038\/s41375-021-01181-w","article-title":"BET proteolysis targeted chimera-based therapy of novel models of Richter transformation-diffuse large B-cell lymphoma","volume":"35","author":"Fiskus","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.semcancer.2026.02.002_bib113","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41375-023-02095-5","article-title":"Chronic lymphocytic leukemia patient-derived xenografts recapitulate clonal evolution to Richter transformation","volume":"38","author":"Playa-Albinyana","year":"2024","journal-title":"Leukemia"},{"key":"10.1016\/j.semcancer.2026.02.002_bib114","doi-asserted-by":"crossref","first-page":"5463","DOI":"10.1182\/blood-2010-12-324210","article-title":"A novel adoptive transfer model of chronic lymphocytic leukemia suggests a key role for T lymphocytes in the disease","volume":"117","author":"Bagnara","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2026.02.002_bib115","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.627020","article-title":"A detailed analysis of parameters supporting the engraftment and growth of chronic lymphocytic leukemia cells in immune-deficient mice","volume":"12","author":"Patten","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.semcancer.2026.02.002_bib116","doi-asserted-by":"crossref","first-page":"3378","DOI":"10.1182\/blood.2020010187","article-title":"Synergistic efficacy of the dual PI3K-\u03b4\/\u03b3 inhibitor duvelisib with the Bcl-2 inhibitor venetoclax in Richter syndrome PDX models","volume":"137","author":"Iannello","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2026.02.002_bib117","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1182\/bloodadvances.2023011690","article-title":"A molecular circuit linking the BCR to the NAD biosynthetic enzyme NAMPT is an actionable target in Richter syndrome","volume":"8","author":"Messana","year":"2024","journal-title":"Blood Adv."},{"key":"10.1016\/j.semcancer.2026.02.002_bib118","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2022016211","article-title":"Anti-CD37 alpha-amanitin conjugated antibodies as potential therapeutic weapons for Richter\u2019s Syndrome","author":"Vaisitti","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2026.02.002_bib119","doi-asserted-by":"crossref","DOI":"10.1007\/s00018-025-05670-4","article-title":"Complementary approaches define the metabolic features that accompany Richter syndrome transformation","volume":"82","author":"Omezzolli","year":"2025","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.semcancer.2026.02.002_bib120","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.3390\/cancers12061396","article-title":"Mechanisms of B cell receptor activation and responses to B cell receptor inhibitors in B cell malignancies","volume":"12","author":"Efremov","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.semcancer.2026.02.002_bib121","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1182\/blood-2014-12-610782","article-title":"The efficacy of ibrutinib in the treatment of Richter syndrome","volume":"125","author":"Tsang","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2026.02.002_bib122","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/bjh.15440","article-title":"BCR kinase inhibitors, idelalisib and ibrutinib, are active and effective in Richter syndrome","volume":"185","author":"Visentin","year":"2019","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.semcancer.2026.02.002_bib123","doi-asserted-by":"crossref","first-page":"e912","DOI":"10.1016\/S2352-3026(21)00305-7","article-title":"Acalabrutinib monotherapy for treatment of chronic lymphocytic leukaemia (ACE-CL-001): analysis of the Richter transformation cohort of an open-label, single-arm, phase 1\u20132 study","volume":"8","author":"Eyre","year":"2021","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.semcancer.2026.02.002_bib124","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000870","article-title":"Zanubrutinib, alone and in combination with tislelizumab, for the treatment of Richter transformation of chronic lymphocytic leukemia","volume":"7","author":"Tam","year":"2023","journal-title":"Hemasphere"},{"key":"10.1016\/j.semcancer.2026.02.002_bib125","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-019-5717-y","volume":"19","author":"Appleby","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.semcancer.2026.02.002_bib126","first-page":"259","article-title":"Safety and efficacy of the combination of copanlisib and nivolumab in patients with Richter\u2019s transformation or transformed non-Hodgkin lymphoma: results from a phase I trial","volume":"111","author":"Shouse","year":"2026","journal-title":"Haematologica"},{"key":"10.1016\/j.semcancer.2026.02.002_bib127","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1182\/blood.2021012890","article-title":"High-risk subtypes of chronic lymphocytic leukemia are detectable as early as 16 years prior to diagnosis","volume":"139","author":"Kolijn","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2026.02.002_bib128","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1182\/blood.2023019609","article-title":"Genetic drivers in the natural history of chronic lymphocytic leukemia development as early as 16 years before diagnosis","volume":"142","author":"Kolijn","year":"2023","journal-title":"Blood"}],"container-title":["Seminars in Cancer Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044579X26000210?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044579X26000210?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T18:05:23Z","timestamp":1776189923000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1044579X26000210"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":128,"alternative-id":["S1044579X26000210"],"URL":"https:\/\/doi.org\/10.1016\/j.semcancer.2026.02.002","relation":{},"ISSN":["1044-579X"],"issn-type":[{"value":"1044-579X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The biology and evolution of Richter transformation in chronic lymphocytic leukemia","name":"articletitle","label":"Article Title"},{"value":"Seminars in Cancer Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semcancer.2026.02.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}